Luminex Corp. (NASDAQ:LMNX) had its target price reduced by Wedbush from $19.00 to $18.00 in a research note released on Tuesday morning, AnalystRatings.NET reports. They currently have a neutral rating on the stock.
Shares of Luminex Corp. (NASDAQ:LMNX) traded down 1.15% during mid-day trading on Tuesday, hitting $18.00. 64,411 shares of the company’s stock traded hands. Luminex Corp. has a 52-week low of $15.39 and a 52-week high of $24.10. The stock has a 50-day moving average of $19.38 and a 200-day moving average of $19.96. The company has a market cap of $745.1 million and a P/E ratio of 104.66.
Luminex Corp. (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.02 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.11 by $0.09. The company had revenue of $50.80 million for the quarter, compared to the consensus estimate of $54.67 million. During the same quarter last year, the company posted $0.04 earnings per share. Luminex Corp.’s revenue was up 1.6% compared to the same quarter last year. Analysts expect that Luminex Corp. will post $0.40 EPS for the current fiscal year.
A number of other firms have also recently commented on LMNX. Analysts at UBS AG cut their price target on shares of Luminex Corp. from $24.00 to $21.50 in a research note to investors on Tuesday. They now have a neutral rating on the stock. Analysts at TheStreet downgraded shares of Luminex Corp. from a buy rating to a hold rating in a research note to investors on Wednesday, August 21st. One analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. The company presently has an average rating of Hold and an average price target of $20.13.
Luminex Corporation (NASDAQ:LMNX)develops, manufactures and sells biological testing technologies and products with applications throughout the life sciences and diagnostics industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.